Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now
Abstract Human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) is a highly aggressive subtype associated with poor prognosis. The advent of HER2-targeted drugs, including monoclonal antibodies, tyrosine-kinase inhibitors (TKIs) and antibody–drug conjugates, has yielded improved...
| المؤلفون الرئيسيون: | , , , , |
|---|---|
| التنسيق: | مقال |
| اللغة: | English |
| منشور في: |
BMC
2023-10-01
|
| سلاسل: | Breast Cancer Research |
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://doi.org/10.1186/s13058-023-01694-5 |